Coordinated increase of γ-secretase reaction products in the plasma of some female Japanese sporadic Alzheimer's disease patients: Quantitative analysis of p3-Alcα with a new ELISA system

Molecular Neurodegeneration

Volumn 6, Issue 1, 2011, Pages

  Konno, Tomoko ^a   Hata, Saori ^a   Hamada, Yukiko ^b   Horikoshi Sakuraba, Yuko ^b   Nakaya, Tadashi ^a   Saito, Yuhki ^a   Yamamoto, Tohru ^a   Yamamoto, Takayuki ^c   Maeda, Masahiro ^b   Ikeuchi, Takeshi ^d   Gandy, Sam ^e,f   Akatsu, Hiroyasu ^c   Suzuki, Toshiharu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b Immuno Biological Laboratories Co Ltd   (Japan)

^c NAGOYA CITY UNIVERSITY   (Japan)

^d NIIGATA UNIVERSITY   (Japan)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f James J Peters Veterans Administration Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; GAMMA SECRETASE; P3 ALCADEIN ALPHA; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN P3, HUMAN; AMYLOID BETA-PROTEIN P3, HUMAN; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; SECRETASE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ENDOPHENOTYPE; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; QUANTITATIVE ANALYSIS; ANIMAL; ASIAN; BLOOD; COHORT ANALYSIS; EVALUATION; METABOLISM; METHODOLOGY; MIDDLE AGED; PLASMA;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTOTEMPORAL LOBAR DEGENERATION; HUMANS; MALE; MIDDLE AGED; PLASMA;

EID: 80455158245     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-6-76     Document Type: Article

References (32)

1. Novel cadherin-related membrane proteins, Alcadeins, enhance the X11-like protein mediated stabilization of amyloid -protein precursor metabolism. Araki Y, Tomita S, Yamaguchi H, Miyagi N, Sumioka A, Kirino Y, Suzuki T, J Biol Chem 2003 278 49448 49458 10.1074/jbc.M306024200 12972431
2. Coordinated metabolism of Alcadein and amyloid -protein precursor regulates FE65-dependent gene transactivation. Araki Y, Miyagi N, Kato N, Yoshida T, Wada S, Nishimura M, Komano H, Yamamoto T, De Strooper B, Yamamoto K, Suzuki T, J Biol Chem 2004 279 24343 24354 10.1074/jbc.M401925200 15037614 (Pubitemid 38725297)
3. The novel cargo receptor Alcadein induces vesicle association of kinesin-1 motor components and activates axonal transport. Araki Y, Kawano T, Taru H, Saito Y, Wada S, Miyamoto K, Kobayashi H, Ishikawa OH, Ohsugi Y, Yamamoto T, Matsuno K, Kinjyo M, Suzuki T, EMBO J 2007 26 1475 1486 10.1038/sj.emboj.7601609 17332754 (Pubitemid 46480935)
4. Alcadein cleavages by APP - and γ-secretases generate small peptides p3-Alcs indicating Alzheimer disease-related γ-secretase dysfunction. Hata S, Fujishige S, Araki Y, Kato N, Araseki M, Nishimura M, Hartmann D, Saftig P, Fahrenholz F, Taniguchi M, Urakami K, Akatsu H, Martins RN, Yamamoto K, Maeda M, Yamamoto T, Nakaya T, Gandy S, Suzuki T, J Biol Chem 2009 284 36024 36033 10.1074/jbc.M109.057497 19864413
5. Alternative processing of γ-secretase substrates in common forms of mild cognitive impairment and Alzheimer's disease: Evidence for γ-secretase dysfunction. Hata S, Fujishige S, Araki Y, Taniguchi M, Urakami K, Peskind E, Akatsu H, Araseki M, Yamamoto K, Martins RN, Maeda M, Nishimura M, Levey A, Chung KA, Montine T, Leverenz J, Fagan A, Goate A, Bateman R, Holtzman DM, Yamamoto T, Nakaya T, Gandy S, Suzuki T, Ann Neurol 2011 69 1026 1031 10.1002/ana.22343 21681798
6. Loss-of-function presenilin mutations in Alzheimer disease. Taking point on the role of presenilin mutations in Alzheimer disease. De Strooper B, EMBO Rep 2007 8 141 146 10.1038/sj.embor.7400897 17268505 (Pubitemid 46420841)
7. Intramembrane proteolysis by γ-secretase. Steiner H, Fluher R, Haass C, J Biol Chem 2008 283 29627 29631 10.1074/jbc.R800010200 18650432
8. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Sherrngton R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin J-F, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A, Sanseau P, Polinsky RJ, Wasco W, Da Silva HAR, Haines JL, Pericak-Vance MA, Tanzi RE, Roses AD, et al. Nature 1995 375 754 760
9. Familial Alzheimer's disease-linked presenilin 1 variants elevate A1-42/1-40 ratio in vitro and in vitro. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia S, Neuron 1996 17 1005 1013 10.1016/S0896-6273(00)80230-5 8938131 (Pubitemid 26424026)
10. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid -peptide. Haass C, Selkoe DJ, Nat Rev Moll Cell Biol 2007 8 101 112 (Pubitemid 46432529)
11. Amyloid- protein dimers isolated directly from Alzheimer's brain impair synaptic plasticity and memory. Shankar GM, Li S, Methta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ, Nat Med 2008 14 837 842 10.1038/nm1782 18568035
12. Alzheimer's Disease Neuroimaging Initiative: Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, Soares H, Simon AJ, Lewczuk P, Dean RA, Siemers E, Potter W, Lee VM, Trojanowski JQ, Acta Neuropathol 2011 121 597 609 10.1007/s00401-011-0808-0 21311900
13. Amyloid protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature. Frankfort SV, Tulner LR, van Campen JP, Verbeek MM, Jansen RW, Beijnen JH, Curr Clin Pharmacol 2008 3 123 1331 10.2174/157488408784293723 18700307
14. Association of plasma amyloid with risk of dementia: The prospective three-city study. Lambert JC, Schhraen-Maschke S, Richard F, Fievet N, Rouaud O, Berr C, Dartigues JF, Tzourio C, Alperovitch A, Buee L, Amouyel A, Exp Neurol 2009 73 847 853
15. Association of low plasma A42/A40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Graff-Radford NR, Crook JE, Lucas J, Boeve BT, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG, Arch Neurol 2007 64 354 362 10.1001/archneur.64.3.354 17353377 (Pubitemid 46425689)
16. Association of plasma -amyloid level and cognitive reserve with subsequent cognitive decline. Yaffe K, Weston A, Graff-Radford NR, Satterfield S, Simonsick EM, Younkin SG, Younkin LH, Kuller L, Ayonayon HN, Ding J, Harris TB, JAMA 2011 305 261 266 10.1001/jama.2010.1995 21245181
17. The 28-amino acid form of an APLP1-derived A-like peptide is a surrogate marker for A42 production in the central nervous system. Yanagida K, Okochi M, Tagami S, Nakayama T, Kodama TS, Nishitomi K, Jiang J, Mori K, Tatsumi S, Arai T, Ikeuchi T, Kasuga K, Tokuda T, Kondo M, Ikeda M, Deguchi K, Kazui H, Tanaka T, Morihara T, Hashimoto R, Kudo T, Steiner H, Haass C, Tsuchiya K, Akiyama H, Kuwano R, Takeda M, EMBO Mol Med 2009 1 223 35 10.1002/emmm.200900026 20049724
18. Decreased clearance of CNS -amyloid in Alzheimer's disease. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ, Science 2010 330 1774 10.1126/science.1197623 21148344
19. Apolipoprotein E promotes the binding and uptake of -amyloid into Chinese hamster ovary cells in an isoform-specific manner. Yang DS, Small DH, Seydel U, Smith JD, Hallmayer J, Gandy SE, Martins RN, Neuroscience 1999 90 1217 1226 10.1016/S0306-4522(98)00561-2 10338292 (Pubitemid 29170140)
20. APOE genotype results in differential effects on the peripheral clearance of amyloid-42 in APOE knock-in and knock-out mice. Sharman MJ, Morici M, Hone E, Berger T, Taddei K, Martins IJ, Lim WL, Singh S, Wenk MR, Ghiso J, Buxbaum JD, Gandy S, Martins RN, J Alzheimers Dis 2010 21 403 409 20555142
21. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JS, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, et al. Nat Genet 2011 43 436 41 10.1038/ng.801 21460841
22. Estogen reduces neural generation of Alzheimer -amyloid peptides. Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L, Fried G, Jovanovic JN, Seeger M, Relkin NR, Liao F, Checler F, Buxbaum JD, Chit BT, Thinakaran G, Sisodia SS, Wang R, Greengard P, Gandy S, Nat Med 1998 4 447 451 10.1038/nm0498-447 9546791 (Pubitemid 28212761)
23. Modulation of A peptides by estrogen in mouse models. Zheng H, Xu H, Uljon SN, Gross R, Hardy K, Gaynor J, Lafrancois J, Simpkins J, Refolo LM, Petanceska S, Wang R, Duff K, J Neurochem 2002 80 191 196 10.1046/j.0022-3042. 2001.00690.x 11796757 (Pubitemid 34614591)
24. Analysis of oestrogen regulation of alpha-, beta- and gamma-secretase gene and protein expression in cultured human neuronal and glial cells. Nord LC, Sundgvist J, Anderson E, Fried G, Neurodegener Dis 2010 7 349 364 10.1159/000282279 20523023
25. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Verghese PB, Castellano JM, Holzman DM, Lancet Neurol 2011 10 241 252 10.1016/S1474-4422(10)70325-2 21349439
26. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of -amyloid peptide. Yasojima K, Akiyama H, McGeer EG, McGeer PL, Neurosci Lett 2001 297 97 100 10.1016/S0304-3940(00) 01675-X 11121879
27. Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing. Jordan BD, Relkin NR, Ravdin LD, Jacobs AR, Bennett A, Gandy S, JAMA 1997 278 136 140 10.1001/jama.278.2.136 9214529 (Pubitemid 27287671)
28. A neprilysin polymorphism and amyloid-beta plaques after traumatic brain injury. Johnson VE, Stewart W, Graham DI, Stewart JE, Praestgaard AH, Smith DH, J Neurotrauma 2009 26 1197 1202 10.1089/neu.2008.0843 19326964
29. Traumatic brain injury: football, warfare, and long-term effects. DeKosky ST, Ikonomovic MD, Gandy S, N Engl J Med 2010 363 1293 1296 10.1056/NEJMp1007051 20879875
30. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. Melchor JP, Pawlak R, Strickland S, J Neurosci 2003 23 8867 8871 14523088 (Pubitemid 37210899)
31. The possible role of tissue-type plasminogen activator (tPA) and tPA blockers in the pathogenesis and treatment of Alzheimer's disease. Melchor JP, Pawlak R, Chen Z, Strickland S, J Mol Neurosci 2003 20 287 289 10.1385/JMN:20:3:287 14501010 (Pubitemid 38146984)
32. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DE, Neurology 1998 51 1546 1554